Islet antigen peptide-major histocompatibility complex (null)

The islet antigen peptide-MHC complex is a molecular structure formed when fragments (peptides) of islet autoantigens (such as insulin, GAD65, IA-2) are bound by major histocompatibility complex molecules (MHC class I or II) on the surface of antigen-presenting cells or, under certain inflammatory states, islet β cells themselves[1][2][3][5]. This complex is central to adaptive immunity, serving as the ligand recognized by T cell receptors (CD8+ or CD4+ T cells), and is critically involved in the pathogenesis of type 1 diabetes—where autoimmune T cells target these complexes and destroy insulin-producing β cells[1][2][4][6]. Therapeutic efforts are being made to block, modulate, or induce tolerance towards these complexes as a strategy to prevent or treat autoimmune diabetes[4][1]. The complex does not represent a conventional receptor or enzyme target; rather, it is a composite structure pivotal to the immune recognition process, especially for self versus non-self discrimination and the development of autoimmunity. Targeting this complex presents challenges due to MHC polymorphism and the diversity of islet antigen peptides presented in patient populations[5][4].

Other names

Peptide-MHC complexislet autoantigen-MHC complexpMHC islet complexautoantigen-MHC complex

Monoclonal antibodies may block T cell recognition of autoantigen-MHC complexes, thereby inhibiting autoimmune responses Peptide mimetics or altered peptide ligands can modulate T cell activation by changing the presentation profile Immunotherapies seek to induce tolerance toward islet peptide–MHC complexes